E. Hussey

发表

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

J. Polli, D. Nunez, R. Dobbins, 2013, BMC Pharmacology and Toxicology.

Relative Bioavailability of an Emulsion Formulation for Omega‐3‐Acid Ethyl Esters Compared to the Commercially Available Formulation: A Randomized, Parallel‐Group, Single‐Dose Study Followed by Repeat Dosing in Healthy Volunteers

W. Harris, F. Gao, M. Fossler, 2012, Clinical pharmacology in drug development.

Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment

W. Wilkison, B. Cheatham, R. Dobbins, 2015, Drug Metabolism and Disposition.

Regional gastrointestinal delivery of remogliflozin etabonate in humans

R. Dobbins, R. O'Connor‐Semmes, E. Hussey, 2013, Biopharmaceutics & drug disposition.

Albuterol Extended‐Release Products: A Comparison of Steady‐State Pharmacokinetics

J. Powell, E. Hussey, K. Donn, 1991, Pharmacotherapy.

Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies

J. Polli, M. Reese, J. Humphreys, 2012, Drug Metabolism and Disposition.

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes

S. Mudaliar, R. Henry, D. Armstrong, 2012, Diabetes Care.

Remogli fl ozin Etabonate , a Selective Inhibitor of the Sodium-Glucose Transporter 2 , Improves SerumGlucose Pro fi les in Type 1 Diabetes

S. Mudaliar, R. Henry, D. Armstrong, 2012 .

The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a Phase I study

S. Danner, J. Lange, E. Hussey, 1992, AIDS.

Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials

J. Bartlett, J. Eron, G. E. Pakes, 1999, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Tolerability of a Single Inhaled Dose of Zanamivir in Children

J. Blumer, B. Rosolowski, E. Hussey, 2000 .

Pharmacokinetics of lamivudine administered alone and with trimethoprim‐sulfamethoxazole

J. Eron, E. Hussey, R. Raasch, 1996, Clinical pharmacology and therapeutics.

A Population Pharmacokinetic Analysis of Zanamivir in Subjects with Experimental and Naturally Occurring Influenza: Effects of Formulation and Route of Administration

E. Hussey, A. Peng, K. Moore, 2000, Journal of clinical pharmacology.

Lack of effect of ondansetron on the pharmacokinetics and analgesic effects of morphine and metabolites after single-dose morphine administration in healthy volunteers.

W. Maixner, K. Brouwer, A. Passannante, 2001, British journal of clinical pharmacology.

Interspecies Scaling and Pharmacokinetic Parameters of 3TC in Humans

E. Hussey, A. Harker, K. Donn, 1994, Journal of clinical pharmacology.

A Novel Method for Studying the Pharmacokinetics of [14C]Umeclidinium After Application to the Axilla or Palm of Healthy Male Subjects

E. Hussey, T. Pene Dumitrescu, S. Baptiste-Brown, 2016, Clinical and translational science.

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.

F. Hayden, R. Betts, J. Treanor, 1996, JAMA.

Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors

K. Papadopoulos, A. Naing, S. Piha-Paul, 2020, Journal for ImmunoTherapy of Cancer.

Single dose pharmacokinetics of sumatriptan in healthy volunteers

L. Lacey, P. Fowler, E. Hussey, 2004, European Journal of Clinical Pharmacology.

Do All Histamine2-Antagonists Cause a Warfarin Drug Interaction?

M. Raebel, G. Dukes, E. Hussey, 1989, DICP : the annals of pharmacotherapy.

Sumatriptan Absorption from Different Regions of the Human Gastrointestinal Tract

I. M. Davis, W. Heizer, J. Powell, 2004, Pharmaceutical Research.

Assessment of Acute and Chronic Pharmacological Effects on Energy Expenditure and Macronutrient Oxidation in Humans: Responses to Ephedrine

P. Murgatroyd, A. Napolitano, D. Nunez, 2010, Journal of obesity.

Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects

Sam R. Miller, E. Bullmore, P. Murgatroyd, 2013, Journal of clinical & translational endocrinology.

Single‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

S. Murray, D. Nunez, M. Kipnes, 2010, Journal of clinical pharmacology.

Evaluation of the Pharmacokinetic Interaction Between Diazepam and ACC-9653 (a Phenytoin Prodrug) in Healthy Male Volunteers

Thomas F. Krol, K. Brouwer, J. Messenheimer, 1990, Pharmaceutical Research.

Safety and Efficacy of Once Daily Intranasal Zanamivir in Preventing Experimental Human Influenza a Infection

F. Hayden, D. Calfee, M. Lobo, 1998, Antiviral therapy.

Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza.

F. Hayden, J. Treanor, E. Hussey, 1997, The Journal of infectious diseases.

Oral Sumatriptan Pharmacokinetics in the Migraine State

N. Cutler, J. Sramek, E. Hussey, 1999 .

Pharmacokinetics, Absolute Bioavailability, and Absorption Characteristics of Lamivudine

E. Hussey, G. Yuen, S. Hall, 1995, Journal of clinical pharmacology.

Comparison of Verapamil, Diltiazem, and Labetalol on the Bioavailability and Metabolism of Imipramine

Thomas F. Krol, J. Powell, D. Hermann, 1992, Journal of clinical pharmacology.

Albuterol Extended‐Release Products: Effect of Food on the Pharmacokinetics of Single Oral Doses of Volmax® and Proventil® Repetabs® in Healthy Male Volunteers

J. Powell, E. Hussey, Gary E. Pakes, 1991, Journal of clinical pharmacology.

Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design

J. Polli, D. Nunez, M. Bush, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8

V. Ona, A. Port, A. Bytyqi, 2021, Pharmacology research & perspectives.

Pharmacokinetics of 3TC (GR109714X) Administered With and Without Food to HIV-infected Patients

J. Montaner, J. Ruedy, J. McCormack, 1993 .

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

J. Polli, D. Nunez, R. Dobbins, 2013, BMC Pharmacology and Toxicology.

Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

W. Wilkison, B. Cheatham, R. Dobbins, 2021, BMC pharmacology & toxicology.

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

J. Polli, R. Dobbins, A. Kapur, 2013, BMC Pharmacology and Toxicology.

Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

C. Kapitza, G. Golor, R. Dobbins, 2012, Diabetes, obesity & metabolism.

Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance and Ketoconazole Interaction Studies.

J. Polli, J. Humphreys, R. Dobbins, 2012 .

Correlation of Delayed Peak Concentration with Infusion-Site Irritation following Diazepam Administration

Thomas F. Krol, K. Brouwer, J. Messenheimer, 1990, DICP : the annals of pharmacotherapy.